Please login to the form below

Not currently logged in
Email:
Password:

Proteus: Digital medicines set to transform healthcare

Tells PM Society event that pharma and health systems have reached a pivot point
Proteus Ingestible

New sensor-enabled medicines could transform healthcare for both patients and health providers across the world.

That's according to leading 'digital pill' firm Proteus Digital Health, whose head of customer partnering was speaking at the PM Society's Digital Health Works II event yesterday.

“We are at a cusp, a pivot point, not just for the pharmaceutical industries, but also the way organisations like the NHS think about the way they deliver care as well,” Proteus' Barnaby Poulton told the Digital Health Works II audience in London.

He added: “It is not sustainable to keep going the way we are.”

Proteus' new sensor pills are able to create unique collaborations between patients and doctors as they provide objective insight into numerous factors, primarily how patients actually take their medications.

The sensor itself is composed of small amounts of copper, silicon, and magnesium - the amount you might find in oily fish or a banana. Upon ingesting the pill, a signal is picked up by a plaster worn by the patients which timestamps when the medication was taken before the sensor dissolves. 

The patch worn by the patient is also able to record patient's blood pressure, heart rate as well as their activity levels including step count.

Earlier this month the company marked a key milestone when US regulator the FDA accepted its joint new drug application with Tokyo-based Otsuka Pharmaceuticals.

The companies submitted for approval a sensor-enabled version of Otsuka's Abilify (aripriprazole), a treatment for patients with schizophrenia, bi-polar and other mental health disorders.

Poulton said: “The new digital medication takes what takes place inside a clinical trial, which is a very controlled environment, and translates those results into the real world.

“End products however must provide outstanding usability as well as value to the patient, clinician and payer meaning we have been forced to make some tough investment decisions.”

It is estimated that around 50% of medications in the UK are not taken as prescribed and therefore clinical teams are burdened with extra work involving extra testing and referrals.

In the UK it is thought unused prescription medications cost the NHS around £300m and medication adherence problems, while in the US the problem is responsible for up to $300bn in avoidable healthcare costs.

Article by
Nikhil Patel

23rd September 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....